Status:
UNKNOWN
Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Patients With Non-small Cell Lung Cancer
Eligibility:
All Genders
21+ years
Brief Summary
1. To compare EGFR mutations between primary non-small cell lung cancer (NSCLC) tumours and corresponding CTCs isolated by a label-free microfluidic device-based system 2. To characterize the associat...
Detailed Description
For Aim 1, two 5ml pre-treatment blood and corresponding tumor samples will be obtained from NSCLC patients at the National University Health System. Sampling will be organized to avoid the blood samp...
Eligibility Criteria
Inclusion
- For aim 1:
- Patients with newly diagnosed non-small cell lung cancer who have not received any systemic therapy such as chemotherapy or targeted therapy.
- Age 21 years or above
- For aim 2
- Patients with a diagnosis of non small cell lung cancer
- Receiving gefitinib as part of their treatment for NSCLC
- Age 21 years or above
Exclusion
- Patients unwilling to provide consent
- Patients, who in the opinion of the investigator, are unable to comply with study requirements
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01193829
Start Date
September 1 2010
End Date
December 1 2014
Last Update
April 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore, Singapore